Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2023 - 2024)

Spyre Therapeutics' Preferred Stock Liabilities history spans 4 years, with the latest figure at $253.4 million for Q1 2024.

  • For Q1 2024, Preferred Stock Liabilities changed N/A year-over-year to $253.4 million; the TTM value through Mar 2024 reached $253.4 million, changed N/A, while the annual FY2023 figure was $84.6 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $253.4 million in Q1 2024 per SYRE's latest filing, up from $84.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $387.1 million in Q3 2023 to a low of $84.6 million in Q4 2023.